Pharamaceutical Outsourcing - Executive Summary

Published on: 10/02/2017

The industry has seen a wave of high-profile acquisitions in 2017 in all major subsectors of pharma outsourcing including contract manufacturing, drug discovery services, CRO and analytical testing. Private equity have been active acquirers willing to pay valuation premiums for platforms with scale and differentiated capabilities as evidenced by the recent AMRI and PAREXEL deals; both of which were acquired by equity groups at double digit EBITDA multiples.



Key Contacts